链霉蛋白酶治疗幽门螺杆菌感染的研究进展

幽门螺杆菌(Helicobacter pylori,H.pylori)是一种可引发多系统病变的致病微生物。根除H.pylori能够改善胃黏膜炎性反应,阻止或延缓胃黏膜萎缩、肠化生的发生和发展,并部分逆转萎缩,也可不同程度地降低胃癌的发生率。以往临床常采用三联疗法作为根除H.pylori的一线治疗方案,但近年由于抗生素的广泛使用,导致H.pylori的抗药性增强,根除率降低。国内外研究均表明,链霉蛋白酶可以通过抑制H.pylori生存和影响抗H.pylori抗菌药起到根治的作用,并且在此方面取得良好疗效,为根除H.pylori开辟出一条崭新的道路。本文就链霉蛋白酶治疗H.pylori的进展作一概述。

Progress of pronase in the treatment of Helicobacter pylori infection

Helicobacter pylori(H.pylori)is a pathogenic microorganism that causes multisystem diseases.Eradication of H.pylori can improve the inflammatory response of gastric mucosa,prevent or delay the occurrence and development of mucosal atrophy and intestinal metaplasia,partially reverse atrophy,and reduce the incidence of gastric cancer to varying degrees.In the past,triple therapy was often used as the first-line treatment for H.pylori eradication.However,the eradication rate of H.pylori has decreased due to the widespread use of antibiotics.Domestic and foreign studies have shown that pronase has good efficacy in the treatment of H.pylori by inhibiting the survival of H.pylori and affecting antibacterial drugs,which paves a new way for eradicating H.pylori.This article reviewed the progress of pronase in the treatment of H.pylori.